6. Simpozij 07. -10. 11. 2013.g
ESMO RSS- FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation 30. listopada 2025.
- Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC 29. listopada 2025.
- EMA Recommends Extension of Indications for Sugemalimab 28. listopada 2025.
- Marking Breast Cancer Awareness Month 2025, ESMO Calls for Increasing Awareness of the Cancer Risks Posed by Alcohol & the Development of Robust Policy Measures to Prevent Breast Cancer Cases 27. listopada 2025.
